Rituximab for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Details

Details

Files

Generic Name:

Rituximab

Project Status:

Cancelled

Manufacturer:

Sandoz Canada

Brand Name:

TBD

Project Line:

Reimbursement Review

Project Number:

PC0180-000

Tumour Type:

Lymphoma & Leukemia

Indications:

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar

Funding Request:

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia

Review Status:

Cancelled

Pre Noc Submission:

Yes

Sponsor:

Sandoz Canada

Clarification:

The submitter notified pCODR that they will not be filing the submission.

Files

Rituximab (TBD) Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia - Registered Clinician Input Template View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : April 29, 2019